Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas.

Trial Profile

Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 May 2015

At a glance

  • Drugs CAT 3888 (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 21 Jun 2010 Trial sponsor and lead centre (MedImmune) added as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Trial sponsor and lead centre (MedImmune) added as reported by ClinicalTrials.gov.
    • 21 Jun 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top